Find Reports
Select Report Type
Reimbursement Review
Displaying 176 - 200 of 1258
Please scroll or swipe to the right to view the full content.
| Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|
| Gavreto | pralsetinib | RET fusion-positive non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0283-000 | |||
| Verzenio | abemaciclib | Adjuvant treatment of HR-positive, HER2-negative early breast cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0282-000 | |||
| Keytruda | pembrolizumab | Renal cell carcinoma, adjuvant | Reimburse with clinical criteria and/or conditions | Complete | PC0273-000 | |||
| Minjuvi | tafasitamab | Diffuse large B-cell lymphoma (DLBCL) | Do not reimburse | Complete | PC0266-000 | |||
| Lutathera | lutetium oxodotreotide | Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) | Reimburse with clinical criteria and/or conditions | Complete | PC0284-000 | |||
| Enhertu | trastuzumab deruxtecan | Metastatic HER2 positive breast cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0285-000 | |||
| Opdivo | nivolumab | Urothelial carcinoma | Reimburse with clinical criteria and/or conditions | Complete | PC0272-000 | |||
| Retevmo | selpercatinib | Thyroid cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0264-000 | |||
| Wegovy | semaglutide | Weight management | Do not reimburse | Complete | SR0725-000 | |||
| Jakavi | ruxolitinib | Graft versus host disease | Reimburse with clinical criteria and/or conditions | Complete | SR0688-000 | |||
| Keytruda and Lenvima | pembrolizumab and lenvatinib | Advanced endometrial cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0288-000 | |||
| Tecentriq | atezolizumab | Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0277-000 | |||
| Tecentriq | atezolizumab | Non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0269-000 | |||
| Keytruda | pembrolizumab | Triple-negative breast cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0279-000 | |||
| Tepmetko | tepotinib | Locally advanced or metastatic non-small cell lung cancer | Do not reimburse | Complete | PC0255-000 | |||
| Jemperli | dostarlimab | Endometrial cancer | Do not reimburse | Complete | PC0263-000 | |||
| Cibinqo | abrocitinib | Atopic dermatitis, moderate to severe | Reimburse with clinical criteria and/or conditions | Complete | SR0686-000 | |||
| Vabysmo | faricimab | Macular degeneration, age-related | Reimburse with clinical criteria and/or conditions | Complete | SR0719-000 | |||
| Poteligeo | mogamulizumab | mycosis fungoides (MF), Sézary syndrome (SS) | Reimburse with clinical criteria and/or conditions | Complete | PC0244-000 | |||
| Spinraza | nusinersen | Spinal Muscular Atrophy | Do not reimburse | Complete | SR0713-000 | |||
| Scemblix | asciminib | Philadelphia chromosome-positive chronic myeloid leukemia | Reimburse with clinical criteria and/or conditions | Complete | PC0275-000 | |||
| Xpovio | selinexor | Multiple myeloma | Reimburse with clinical criteria and/or conditions | Complete | PC0276-000 | |||
| Brukinsa | zanubrutinib | Mantle cell lymphoma (MCL) | Do not reimburse | Complete | PC0267-000 | |||
| Albrioza | sodium phenylbutyrate and ursodoxicoltaurine | Amyotrophic lateral sclerosis (ALS) | Reimburse with clinical criteria and/or conditions | Complete | SR0711-000 | |||
| Jakavi | ruxolitinib | Graft versus host disease | Reimburse with clinical criteria and/or conditions | Complete | SR0706-000 |
Health Technology Review
Displaying 176 - 200 of 589
Please scroll or swipe to the right to view the full content.
Horizon Scan
Displaying 101 - 111 of 111
Projects in Progress
Displaying 26 - 40 of 40
View All Reports
Displaying 176 - 200 of 2093
Please scroll or swipe to the right to view the full content.
| Title | Description | Files | Last Updated Sort ascending | Project Line | Project Sub Line | Status | Project Number |
|---|---|---|---|---|---|---|---|
| Multiple Myeloma | Reimbursement Review | Provisional Funding Algorithm | Open for Stakeholder Input | PH0060-000 | |||
| NSCLC without actionable oncogenic alterations | Reimbursement Review | Provisional Funding Algorithm | Open for Stakeholder Input | PH0059-000 | |||
| trofinetide | Reimbursement Review | Active | SR0829-000 | ||||
| durvalumab, tremelimumab | Reimbursement Review | Active | PC0390-000 | ||||
| Overview of Systematic Reviews of Immune Checkpoint Inhibitors in Non–Small-Cell Lung Cancer with EGFR, ALK, ROS1, and RET Actionable Driver Mutations | Health Technology Review | Systematic Review | Completed | RE0050-000 | |||
| Utilization of Cancer Therapies for Advanced Non–Small Cell Lung Cancer With an Oncogenic Driver Mutation | Health Technology Review | Technology Review | Completed | HC0084-OS0008 | |||
| Enzalutamide | Reimbursement Review | Complete | PX0366-000 | ||||
| remdesivir | Reimbursement Review | Complete | SR0834-000 | ||||
| ciltacabtagene autoleucel | Reimbursement Review | Active | PG0361-000 | ||||
| ruxolitinib | Reimbursement Review | Active | SR0835-000 | ||||
| Benchmarking CT and MRI exams | Health Technology Review | In Progress | CM0016-000 | ||||
| Virtual remote CT and MRI | Health Technology Review | In Progress | CM0017-000 | ||||
| Optimal Wait Times | Health Technology Review | In Progress | CM0014-000 | ||||
| aflibercept 8mg/0.07mL | Reimbursement Review | Complete | SR0813-000 | ||||
| pembrolizumab | Reimbursement Review | Complete | PC0344-000 | ||||
| durvalumab | Reimbursement Review | Suspended | PC0372-000 | ||||
| Long-Acting Inhaled Drugs for Chronic Obstructive Pulmonary Disease | Health Technology Review | Therapeutic Review | Active | TR0016-000 | |||
| Adult Classical Hodgkin Lymphoma | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0052-000 | |||
| pegcetacoplan | Reimbursement Review | Active | SR0810-000 | ||||
| Care for Adults Following Laryngectomy | Health Technology Review | Rapid Review | Active | RC1551-000 | |||
| pembrolizumab | Reimbursement Review | Complete | PC0343-000 | ||||
| elranatamab | Reimbursement Review | Complete | PC0315-000 | ||||
| abemaciclib | Reimbursement Review | Active | PC0345-000 | ||||
| aflibercept 8mg/0.07mL | Reimbursement Review | Complete | SR0812-000 | ||||
| Midazolam Compared With Lorazepam in Adults to Control Seizures | Health Technology Review | Rapid Review | Completed | RC1554-000 |